Abstract
As a targeted immunosuppressive drug, rituximab is commonly used in the treatment of lymphoma.Recently, its efficacy in the treatment of rheumatic diseases has been concerned.However, studies have found that the dosage of rituximab for systemic lupus erythematosis (SLE) simply followed that for B-cell lymphoma may lead to increased infection risk. This article reviews the clinical application of low-dose rituximab in treatment of SLE with refractory thrombocytopenia, thrombotic thrombocytopenic purpura, lupus nephritis or neuropsychiatric lupus, which suggests that the low-dose rituximab has achieved satisfactory efficacy with good safety and tolerability. Key words: Lupus erythematosus, systemic; Rituximab
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
